Ztlido Generic Name & Formulations
Lidocaine 1.8%; topical system.
Postherpetic neuralgia (PHN).
Ztlido Dosage and Administration
Apply to intact skin, covering most painful area. To adjust dose, cut patches before removing release liner. Remove if irritation or burning occurs; do not reapply until irritation subsides. May apply up to 3 patches at once for up to 12hrs of a 24-hour period. Hepatic impairment or debilitated: use smaller treatment areas.
Ztlido Boxed Warnings
Do not apply to broken or inflamed skin. Avoid eyes, longer duration of application, and application of more than 3 patches. Avoid direct external heat sources (eg, heating pads, electric blankets). Accidental exposure to children and pets. Risk of methemoglobinemia (esp. in G6PD deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants <6 months of age, concurrent exposure to oxidizing agents or metabolites); monitor. Potential cross-sensitivity with allergy to PABA derivatives (eg, procaine, tetracaine, benzocaine). Hepatic disease. Small patients. Pregnancy. Nursing mothers.
Increased risk of methemoglobinemia when concurrently exposed to nitrates/nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, others. Toxicity may be potentiated by Class I antiarrhythmics (eg, tocainide, mexiletine). Additive effects with other products containing local anesthetics.
Ztlido Adverse Reactions
Applications site reactions (eg, irritation, erythema, pruritus); hypersensitivity reactions.
Ztlido Clinical Trials
Ztlido Patient Counseling